NZ597731A - Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof - Google Patents

Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Info

Publication number
NZ597731A
NZ597731A NZ597731A NZ59773108A NZ597731A NZ 597731 A NZ597731 A NZ 597731A NZ 597731 A NZ597731 A NZ 597731A NZ 59773108 A NZ59773108 A NZ 59773108A NZ 597731 A NZ597731 A NZ 597731A
Authority
NZ
New Zealand
Prior art keywords
xanthene
acridine
anthracene
dibenzosuberone
fluorene
Prior art date
Application number
NZ597731A
Other languages
English (en)
Inventor
Wieslaw M Cholody
Original Assignee
Avalon Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Avalon Pharmaceuticals filed Critical Avalon Pharmaceuticals
Publication of NZ597731A publication Critical patent/NZ597731A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/02—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/20—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
    • C07D295/26—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Quinoline Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Furan Compounds (AREA)
  • Indole Compounds (AREA)
NZ597731A 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof NZ597731A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US92859207P 2007-05-10 2007-05-10
US99915307P 2007-10-15 2007-10-15
NZ581647A NZ581647A (en) 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Publications (1)

Publication Number Publication Date
NZ597731A true NZ597731A (en) 2013-08-30

Family

ID=40002552

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ597731A NZ597731A (en) 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
NZ581647A NZ581647A (en) 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ581647A NZ581647A (en) 2007-05-10 2008-05-09 Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Country Status (17)

Country Link
US (3) US8129519B2 (enExample)
EP (1) EP2152258B1 (enExample)
JP (2) JP5782586B2 (enExample)
KR (1) KR101486026B1 (enExample)
CN (2) CN108314663B (enExample)
AU (1) AU2008251800B2 (enExample)
CA (2) CA2871493C (enExample)
DK (1) DK2152258T3 (enExample)
ES (1) ES2584188T3 (enExample)
HU (1) HUE029155T2 (enExample)
IL (2) IL202039A (enExample)
MX (2) MX2009011970A (enExample)
NZ (2) NZ597731A (enExample)
PL (1) PL2152258T3 (enExample)
PT (1) PT2152258T (enExample)
WO (1) WO2008140792A1 (enExample)
ZA (1) ZA200907859B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2871493C (en) * 2007-05-10 2017-03-28 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
US8466149B2 (en) * 2007-08-15 2013-06-18 Merck Sharp & Dohme Corp. 6-substituted sulfonyl azabicyclo[3.2.1]octanes useful to inhibit 11β-hydroxysteroid dehydrogenase type-I
WO2011019651A1 (en) 2009-08-10 2011-02-17 Epitherix, Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
KR101161290B1 (ko) 2009-10-16 2012-07-02 에스에프씨 주식회사 축합방향족화합물 및 이를 이용한 유기전계발광소자
SMT201700581T1 (it) 2009-12-21 2018-01-11 Samumed Llc 1h-pirazolo[3,4-b]piridine e loro usi terapeutici
EP3473099A1 (en) 2011-09-14 2019-04-24 Samumed, LLC Indazole-3-carboxamides and their use as wnt/b-catenin signaling pathway inhibitors
AU2012332111B2 (en) * 2011-11-06 2016-11-17 Beta Cat Pharmaceuticals, Llc Methods for treatment of diseases and disorders related to transducin beta-like protein 1 (TBL 1) activity, including myeloproliferative neoplasia and chronic myeloid leukemia
US20130123281A1 (en) * 2011-11-11 2013-05-16 Beta Cat Pharmaceuticals, Llc Compositions and Methods for Inhibition of TBL-1 Binding to Disease-Associated Molecules
PH12017500997A1 (en) 2012-04-04 2018-02-19 Samumed Llc Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof
NZ629282A (en) 2012-05-04 2017-04-28 Samumed Llc 1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
CA2897400A1 (en) 2013-01-08 2014-07-17 Samumed, Llc 3-(benzoimidazol-2-yl)-indazole inhibitors of the wnt signaling pathway and therapeutic uses thereof
WO2016040193A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040180A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040182A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-1h-imidazo[4,5-c]pyridine and therapeutic uses thereof
WO2016040188A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040190A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridine and therapeutic uses thereof
WO2016040184A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(3h-imidazo[4,5-b]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
WO2016040185A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof
WO2016040181A1 (en) 2014-09-08 2016-03-17 Samumed, Llc 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridine and therapeutic uses thereof
AU2015334842B2 (en) * 2014-10-24 2022-02-17 Koninklijke Philips N.V. Medical prognosis and prediction of treatment response using multiple cellular signaling pathway activities
US9725473B2 (en) * 2015-07-28 2017-08-08 Beta Cat Pharmaceuticals, Inc. Anthracene-9, 10-dione dioxime compound prodrugs and their uses
WO2017023972A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-imidazo[4,5-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206908B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[3,2-C]pyridin-2-YL)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
US10604512B2 (en) 2015-08-03 2020-03-31 Samumed, Llc 3-(1H-indol-2-yl)-1H-indazoles and therapeutic uses thereof
WO2017023993A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-indol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10383861B2 (en) 2015-08-03 2019-08-20 Sammumed, LLC 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017024003A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10285982B2 (en) 2015-08-03 2019-05-14 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[3,4-C]pyridines and therapeutic uses thereof
WO2017023987A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
WO2017024021A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017023989A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-benzo[d]imidazol-2-yl)-1h-pyrazolo[4,3-b]pyridines and therapeutic uses thereof
US10206909B2 (en) 2015-08-03 2019-02-19 Samumed, Llc 3-(1H-pyrrolo[2,3-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024026A1 (en) 2015-08-03 2017-02-09 Samumed, Llc 3-(1h-indol-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof
US10188634B2 (en) 2015-08-03 2019-01-29 Samumed, Llc 3-(3H-imidazo[4,5-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017023996A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[2,3-b]pyridin-2-yl)-1h-pyrazolo[3,4-b]pyridines and therapeutic uses thereof
US10329309B2 (en) 2015-08-03 2019-06-25 Samumed, Llc 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
US10519169B2 (en) 2015-08-03 2019-12-31 Samumed, Llc 3-(1H-pyrrolo[2,3-C]pyridin-2-yl)-1 H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof
WO2017024010A1 (en) 2015-08-03 2017-02-09 Samumed, Llc. 3-(1h-pyrrolo[3,2-c]pyridin-2-yl)-1h-indazoles and therapeutic uses thereof
WO2017058716A1 (en) * 2015-09-28 2017-04-06 Vivace Therapeutics, Inc. Tricyclic compounds
JP6982748B2 (ja) 2015-11-06 2021-12-17 バイオスプライス セラピューティクス インコーポレイテッド ２−（１Ｈ−インダゾール−３−イル）−３Ｈ−イミダゾ［４，５−ｃ］ピリジンおよびそれらの抗炎症的使用
AR108325A1 (es) 2016-04-27 2018-08-08 Samumed Llc Isoquinolin-3-il carboxamidas y preparación y uso de las mismas
SI3464285T1 (sl) 2016-06-01 2023-02-28 Biosplice Therapeutics, Inc. Postopek za pripravo N-(5-(3-(7-(3-fluorofenil)-3H-imidazo(4,5-C)piridin-2-il)-1H-indazol-5- il)piridin-3-il)-3-metilbutanamida
CN106106481B (zh) * 2016-06-16 2019-06-28 湖北工业大学 一种棉铃虫甾醇载体蛋白2抑制剂及其虚拟筛选方法
KR102593742B1 (ko) 2016-10-21 2023-10-24 사뮤메드, 엘엘씨 인다졸-3-카복사마이드를 사용하는 방법 및 wnt/b-카테닌 신호전달 경로 억제제로서의 그들의 용도
JP7630905B2 (ja) 2016-11-07 2025-02-18 バイオスプライス セラピューティクス インコーポレイテッド 単回用量の調整済み注射用製剤
WO2018118711A1 (en) 2016-12-19 2018-06-28 The Trustees Of Columbia University In The City Of New York Small molecule ferroptosis inducers
EP4656191A1 (en) * 2017-06-02 2025-12-03 Iterion Therapeutics, Inc. Methods for treatment of fibrotic diseases
CA3101994A1 (en) * 2018-06-01 2019-12-05 Iterion Therapeutics, Inc. Formulations of tegavivint and related compounds
KR20210035805A (ko) 2018-06-15 2021-04-01 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 세포후 신호전달 인자의 조절을 통한 면역 활성의 증가
US20230114107A1 (en) 2019-12-17 2023-04-13 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
US11136307B1 (en) * 2020-09-29 2021-10-05 Iterion Therapeutics, Inc. Crystalline form of tegavivint, method of preparation, and use thereof
US11571388B2 (en) 2020-11-24 2023-02-07 Iterion Therapeutics, Inc. Lyophilized formulations of tegavivint
CN117567385B (zh) * 2023-11-23 2024-04-30 中国人民解放军军事科学院军事医学研究院 一种靶向clec5a的小分子抑制剂及其应用
CN119409635A (zh) * 2024-11-04 2025-02-11 河南师范大学 具有抗癌活性的氟代甲基取代茚并[1,2-b]吡啶类化合物及其合成方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3627791A (en) * 1968-11-21 1971-12-14 Richardson Merrell Inc Bis(aminoalkylsulfamoyl) anthraquinones
US3983248A (en) 1968-11-21 1976-09-28 Richardson-Merrell Inc. Bis(aminoalkylsulfamoyl)anthraquinone antiviral agents
US3829578A (en) * 1970-12-10 1974-08-13 Richardson Merrell Inc Antiviral compositions containing bis-basic ethers and thioethers of xanthene and xanthen-9-ones and methods of treating viruses therewith
US3714194A (en) * 1971-06-09 1973-01-30 Upjohn Co Di(azidosulfonyl)xanthones
US3919211A (en) * 1973-02-12 1975-11-11 American Home Prod 9-Oxoxanthene-N,N{40 -bis(substituted)-2,7-disulfonamides
US3981248A (en) * 1975-02-28 1976-09-21 Hall Ski-Lift Company, Inc. Timing gate for ski-lifts
US4250097A (en) * 1978-03-08 1981-02-10 Syntex (U.S.A.) Inc. Compositions for and a method of preventing diabetic complications
US4276224A (en) * 1978-06-07 1981-06-30 Ciba-Geigy Corporation Anthraquinone sulphonamide compounds and preparation
DE3044072A1 (de) * 1980-11-24 1982-07-15 Hoechst Ag, 6000 Frankfurt Bis-aminomehtyl-anthrachinon-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung
IT1223302B (it) 1987-09-16 1990-09-19 Baldacci Lab Spa Composti solfonamido derivati inibitori del sistema enzimatico aldoso-reduttasi e composizioni farmaceutiche che li contengono
HUT67314A (en) * 1993-04-09 1995-03-28 Egyt Gyogyszervegyeszeti Gyar Process for prepg. new trisubstituted cykloalkane deriv.s and pharmaceutical compn.s contg. them
AU2001269291A1 (en) * 2000-07-07 2002-02-05 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
WO2002011574A1 (en) * 2000-08-10 2002-02-14 Benetton Group S.P.A. Sports shoe
CA2473170A1 (en) * 2002-01-15 2003-07-24 Cancer Research Technology Limited Therapeutic acridone and acridine compounds
US6693136B1 (en) * 2002-07-26 2004-02-17 Abbott Laboratories Fluorenes and anthracenes that inhibit P2X3 and P2X2/3 containing receptors
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
CA2871493C (en) * 2007-05-10 2017-03-28 Dogwood Pharmaceuticals, Inc. Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof

Also Published As

Publication number Publication date
JP2014193863A (ja) 2014-10-09
US9446021B2 (en) 2016-09-20
HUE029155T2 (hu) 2017-02-28
JP5782586B2 (ja) 2015-09-24
EP2152258B1 (en) 2016-05-04
ES2584188T3 (es) 2016-09-26
CA2686402C (en) 2015-04-28
CA2871493C (en) 2017-03-28
KR101486026B1 (ko) 2015-01-22
IL202039A (en) 2015-02-26
CN108314663B (zh) 2022-05-13
MX354256B (es) 2018-02-20
CA2871493A1 (en) 2008-11-20
EP2152258A1 (en) 2010-02-17
DK2152258T3 (en) 2016-08-22
WO2008140792A1 (en) 2008-11-20
IL236827A (en) 2017-11-30
US8129519B2 (en) 2012-03-06
US9120754B2 (en) 2015-09-01
IL202039A0 (en) 2010-06-16
NZ581647A (en) 2012-02-24
MX2009011970A (es) 2010-02-12
JP6352017B2 (ja) 2018-07-04
PL2152258T3 (pl) 2017-09-29
PT2152258T (pt) 2016-08-18
JP2010526813A (ja) 2010-08-05
CA2686402A1 (en) 2008-11-20
AU2008251800A1 (en) 2008-11-20
KR20100017768A (ko) 2010-02-16
EP2152258A4 (en) 2011-09-21
US20120129837A1 (en) 2012-05-24
AU2008251800B2 (en) 2014-07-10
ZA200907859B (en) 2012-01-25
US20100137354A1 (en) 2010-06-03
CN108314663A (zh) 2018-07-24
CN101730531A (zh) 2010-06-09
US20150313873A1 (en) 2015-11-05

Similar Documents

Publication Publication Date Title
NZ597731A (en) Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof
TNSN05007A1 (en) Novel thiophenylglycoside derivatives, methods for production thereof, medicaments comprising said compounds and use thereof.
TW200726753A (en) 2,4-diamino-pyrimidines as aurora inhibitors
ATE523487T1 (de) 2-methylen-1-alpha-dihydroxy-19,21-dinor-vitami - d3-analoga und ihre anwendung
MY142018A (en) Thiophene derivatives as chk 1 inihibitors
WO2009046841A8 (de) Piperidin- und piperazinderivate zur behandlung von tumoren
MY150538A (en) Process for the manufacture of dihydropteridinones
PT1984357E (pt) Compostos de 2,4-pirimidinadiamina para tratamento ou prevenção de doenças autoimunes
WO2007009755A3 (en) Compositions and methods for cancer diagnostics comprising pan-cancer markers
MX2009005011A (es) Imidazopirazinas como inhibidores de proteina quinasa.
MY142988A (en) Novel aminobenzophenone compounds
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
TW200630374A (en) Thiazolyldihydroindazoles
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
IL183636A0 (en) Quinoline derivative, use and production thereof, and drug containing the same
ATE521609T1 (de) Aminothiazolylpyrimidinderivate und ihre verwendung bei der behandlung von krebs
WO2005105753A3 (en) Naphthalimide derivatives, methods for their production and pharmaceutical compositions therefrom
WO2004031402A3 (en) Methylation profile of cancer
WO2010034006A3 (en) The putative tumor suppressor microrna-101 modulates the cancer epigenome by repressing the polycomb group protein ezh2.
GB2469980A (en) Novel napthalimide-benzimidazole hybrids as potential antitumour agents and process for the preparation thereof
TW200621703A (en) Alkylidene-tetrahydronaphthalene derivatives, process for their production and their use as anti-inflammatory agents
ATE554774T1 (de) 2-methylen-19-nor-(20s-24epi)-1alpha,25- dihydrovitamin-d2
EP2142518A4 (en) 3,4-DIHYDROQUINAZOLINE DERIVATIVES
DE502004007950D1 (en) Antitumor wirksame 2-substituierte d-homoestra-1,3,5(10)-trien-3-yl sulfamate
HRP20080422T3 (hr) Satraplatin za liječenje rezistentnih ili refraktornih tumora

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 09 MAY 2015 BY SPRUSON + FERGUSON

Effective date: 20140210

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2016 BY COMPUTER PACKAGES INC

Effective date: 20150418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2017 BY COMPUTER PACKAGES INC

Effective date: 20160503

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2018 BY COMPUTER PACKAGES INC

Effective date: 20170502

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2019 BY COMPUTER PACKAGES INC

Effective date: 20180418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2020 BY COMPUTER PACKAGES INC

Effective date: 20190418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2021 BY COMPUTER PACKAGES INC

Effective date: 20200418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2022 BY COMPUTER PACKAGES INC

Effective date: 20210418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2023 BY THOMSON REUTERS

Effective date: 20220402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2024 BY THOMSON REUTERS

Effective date: 20230403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 09 MAY 2025 BY THOMSON REUTERS

Effective date: 20240401

LAPS Patent lapsed